Volatile sulphur compounds (VSC), halimeter · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
0.2% zinc sulphate toothpaste led to lower volatile sulphur compounds (VSC) compared with placebo toothpaste (without zinc); GRADE not reported.
1 finding from 1 review
Dentist-reported organoleptic test (OLT) score (scale 0 to 5) · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
It is very uncertain whether 0.2% zinc sulphate toothpaste changes dentist-reported organoleptic test (OLT) score (scale 0 to 5) compared with placebo toothpaste (without zinc) (very low certainty).
1 finding from 1 review
Length (cm) · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Weight (g) after 6 months · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Mean weight‐for‐age z‐score · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Stunting · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Weight‐for‐length/height z‐score at the end of the intervention Weight scale, measurement boards and child growth reference · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Stunted after 6 months · the promotion of growth and prevention of infections in infants less than six months of age
Zinc supplementation showed no clear difference in stunted after 6 months compared with placebo; no treatment (moderate certainty).
1 finding from 1 review
Wasted after 6 months · the promotion of growth and prevention of infections in infants less than six months of age
Zinc supplementation showed no clear difference in wasted after 6 months compared with placebo; no treatment (low certainty).
1 finding from 1 review
Incidence of pneumonia Defined as patient admitted to hospital with a diagnosis of pneumonia Dose: 2 g per day · children aged 2 months to 59 months
Zinc supplementation may leads to lower pneumonia incidence compared with placebo (low certainty).
1 finding from 1 review
Pneumonia prevalence · children aged 2 months to 59 months
Zinc supplementation may leads to lower pneumonia prevalence compared with placebo (low certainty).
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.
1 finding from 1 review